...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Reports Of Exempt Distribution.
Reply New Message
Prev Message Back To Forum Threaded View Next Message

"However, we can't be in a blackout period because Zenith just issued warrants to (most likely) insiders and friends vis a vis, exempt distribution and Resverlogix issued securities to insiders as reported on SEDI, on June 4, 2024."

Guess it's safe to say donny & his motley crew have FA going on "behind the scenes" same old BS 

Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply